Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1138 of 5804
-
Virus cocktail takes on superbugs in cystic fibrosis trial
Disease control Not yet recruitingThis is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF) experiencing pulmonary exacerbations due to antibio…
Phase: PHASE1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill could replace needles for anemia in dialysis patients
Disease control Not yet recruitingThis study is to evaluate the efficacy and safety of QLG1218(daprodustat) following a switch from erythropoiesis-stimulating agent (ESA) in Chinese HD subjects with renal anemia who are currently treated with ESA. The primary objective is to demonstrate non-inferiority of QLG1218…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a common mineral ease teen depression? new trial investigates
Symptom relief Not yet recruitingThe purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
AI-Powered smartwatches could cut hospital readmissions after heart attacks
Disease control Not yet recruitingMyocardial infarction (MI) remains a major threat to human health. Although interventional treatment techniques have advanced rapidly, many patients still experience major adverse cardiovascular events (MACE) and require hospital readmission after discharge. Artificial intelligen…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Glutamine supplement may shield kids from chemo nerve pain
Prevention Not yet recruitingThe goal of this clinical trial is to assess the efficacy of glutamine in preventing the occurrence of vincristine induced neuropathy and to compare the reduction in rate of any dose reductions and premature chemotherapy discontinuation rates due to peripheral neuropathy between …
Phase: PHASE3 • Sponsor: Ain Shams University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
AI-Powered ventilator coach aims to protect lungs in ICU
Disease control Recruiting nowThe REALVENT trial is designed to evaluate whether a real-time, algorithm-driven ventilation feedback strategy can improve lung-protective ventilation (LPV) achievement rates in critically ill patients receiving invasive mechanical ventilation. This multicentre randomised control…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for Crohn's patients: study tests guselkumab after ustekinumab fails
Disease control Recruiting nowThe purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
Phase: PHASE4 • Sponsor: Xian-Janssen Pharmaceutical Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThe goal of this Phase Ib/II interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant solid tumors. This study is divided into two phase…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could common diabetes drugs tame Post-Heart attack inflammation?
Disease control Recruiting nowThe primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial inf…
Phase: PHASE3 • Sponsor: Instituto Mexicano del Seguro Social • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New vaccine aims to protect against common childhood illness
⭐️ VACCINE ⭐️ Not yet recruitingThis is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6 months to 59 years ).
Phase: PHASE1 • Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC
-
New allergy shot strategy aims to stop sneezing and sniffling for good
Symptom relief Not yet recruitingThis is a multicenter, randomized, double-blind, controlled trial to evaluate the efficacy and safety of an enhanced strategy of allergen-specific immunotherapy (ITIT) in the treatment of allergic rhinitis. By recording the changes in CSMS from baseline to post-treatment in the s…
Phase: NA • Sponsor: Renmin Hospital of Wuhan University • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo before transplant aims to beat rare lymphoma
Disease control Not yet recruitingEvaluation of the efficacy and safety of Thiotepa combined with Cyclophosphamide and Busulfan as conditioning regimen before allo-HSCT for the treatment of NK/T cell lymphoma
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to stop rare lymphoma from coming back after transplant
Disease control Not yet recruitingAllogeneic hematopoietic stem cell transplantation is an important treatment method for NK-T cell lymphoma, but the recurrence rate after transplantation is relatively high. Therefore, exploring efficient and low-toxicity maintenance treatment strategies after transplantation is …
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alteratio…
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for advanced colon cancer: drug duo targets tumors
Disease control Not yet recruitingA randomized, controlled, multicenter clinical study of SHR-A1811 combined with bevacizumab for the second-line treatment of metastatic colorectal cancer
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill hopes to tame tough lung cancer
Disease control Recruiting nowSingle dose: Fasting, oral administration, as a single dose, taken with warm water. Multiple doses: Fasting, oral administration, as a single dose, taken with warm water, once daily (dosing frequency may be adjusted based on study data), with 28 days as one cycle.
Phase: PHASE1 • Sponsor: Tongji University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New cocktail of drugs aims to wipe out aggressive breast cancer before surgery
Disease control Not yet recruitingBreast cancer is one of the most common malignant tumors in women, accounting for the first cancer-related death cause in women. In recent years, the incidence has gradually increased, and the trend is younger. In 2022, the estimated number of new cases of female breast cancer wo…
Phase: NA • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Second dose of fat cells may offer new hope for Crohn's fistulas
Disease control Recruiting nowThe ADICROHN-3 study is a prospective, multicenter, open-label cohort study. Its design is supported by the following elements: * The results of the ADICROHN pilot study (EudraCT No. 2013-002602-31) and our 3-year study, which demonstrate an excellent safety profile with a prom…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo aims to deeply shrink rare blood cancer
Disease control Not yet recruitingThis study is a prospective phase II clinical trial designed to evaluate the deep response rate of the ZBR regimen (zanubrutinib combined with reduced-dose bendamustine and CD20 Monoclonal Antibody ) in treatment-naïve symptomatic Waldenström macroglobulinemia (WM) patients. Elig…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New school program aims to tackle myopia, obesity, and mental health in one go
Prevention Not yet recruitingThis study aims to develop and evaluate a scalable, hybrid intervention model for the co-prevention of myopia, obesity, and mental health issues among children. By integrating cognitive behavioral therapy principles, the model targets key modifiable lifestyle factors-including di…
Phase: NA • Sponsor: Fangbiao Tao • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC